Engineered immune cells target blood cancers in groundbreaking trial
Disease control
Recruiting now
This study is testing a new cell therapy called BSB-1001 for adults with certain high-risk blood cancers (AML, ALL, or MDS). The goal is to see if giving these specially engineered immune cells after a donor stem cell transplant is safe and can help prevent the cancer from coming…
Phase: PHASE1, PHASE2 • Sponsor: BlueSphere Bio, Inc • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC